Literature DB >> 18675083

Donor risk index and organ patient index as predictors of graft survival after liver transplantation.

A W Avolio1, M Siciliano, R Barbarino, E Nure, B E Annicchiarico, A Gasbarrini, S Agnes, M Castagneto.   

Abstract

In liver transplantation the identification of risk factors and the risk quantification for each single case represent a field of great interest. There are donor-related and recipient-related risk factors. Donor risk index (DRI) was retrospectively calculated in 223 liver transplant cases. We did not include patients with preoperative diagnosis of hepatocarcinoma and retransplants. The cases were stratified into two classes according to the DRI (low risk, DRI<1.7, and high risk, DRI >or= 1.7). A new index, namely the organ patient index (OPI) was calculated adding the Model for End-stage Liver Disease (MELD) score to the DRI. Patients were stratified into two classes according to the OPI (low risk, OPI <or= 2.85, and high risk, OPI>2.85). The cases with low DRI (n=144) showed better survival than the cases with high DRI (n=82; P< .02). The cases with low OPI (n=173) showed better survival than cases with high OPI (n=50; P< .01). The OPI predicted outcomes better than DRI, increasing the gap in the long-term graft survival between the low- and the high-risk class. The inclusion of the MELD in the new index allowed better prediction of graft survival.

Entities:  

Mesh:

Year:  2008        PMID: 18675083     DOI: 10.1016/j.transproceed.2008.05.070

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  9 in total

1.  Age is not a contraindication for orthotopic liver transplantation: a single institution experience with recipients older than 75 years.

Authors:  C Burcin Taner; Ryan L Ung; Barry G Rosser; Jaime Aranda-Michel
Journal:  Hepatol Int       Date:  2011-06-18       Impact factor: 6.047

2.  Outcomes among older adult liver transplantation recipients in the model of end stage liver disease (MELD) era.

Authors:  Maricar F Malinis; Shu Chen; Heather G Allore; Vincent J Quagliarello
Journal:  Ann Transplant       Date:  2014-09-26       Impact factor: 1.530

Review 3.  Recent advances in the surgical treatment of hepatocellular carcinoma.

Authors:  Zenichi Morise; Norihiko Kawabe; Hirokazu Tomishige; Hidetoshi Nagata; Jin Kawase; Satoshi Arakawa; Rie Yoshida; Masashi Isetani
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

4.  Liver transplant recipients with portal vein thrombosis receiving an organ from a high-risk donor are at an increased risk for graft loss due to hepatic artery thrombosis.

Authors:  Jonathan G Stine; Curtis K Argo; Shawn J Pelletier; Daniel G Maluf; Patrick G Northup
Journal:  Transpl Int       Date:  2016-10-06       Impact factor: 3.782

Review 5.  Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation.

Authors:  Maurizio Pompili; Giampiero Francica; Francesca Romana Ponziani; Roberto Iezzi; Alfonso Wolfango Avolio
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

6.  Machine-Learning Algorithms Predict Graft Failure After Liver Transplantation.

Authors:  Lawrence Lau; Yamuna Kankanige; Benjamin Rubinstein; Robert Jones; Christopher Christophi; Vijayaragavan Muralidharan; James Bailey
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

7.  Evaluation of standard liver volume formulae for Chinese adults.

Authors:  Zheng-Rong Shi; Lu-Nan Yan; Bo Li; Tian-Fu Wen
Journal:  World J Gastroenterol       Date:  2009-08-28       Impact factor: 5.742

8.  Decision making in liver transplantation--limited application of the liver donor risk index.

Authors:  Leslie Mataya; Andrew Aronsohn; J Richard Thistlethwaite; Lainie Friedman Ross
Journal:  Liver Transpl       Date:  2014-07       Impact factor: 5.799

9.  Prediction of postoperative mortality in liver transplantation in the era of MELD-based liver allocation: a multivariate analysis.

Authors:  Helge Bruns; Vladimir J Lozanovski; Daniel Schultze; Norbert Hillebrand; Ulf Hinz; Markus W Büchler; Peter Schemmer
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.